For an 81‑year‑old man who has completed three days of IV antibiotics for sepsis and is clinically stable with normal renal function, can I switch to oral cephalexin and what is the appropriate dosing?

Oral Cephalexin for Sepsis Step-Down Therapy

Yes, you can switch to oral cephalexin for this clinically stable 81-year-old man after 3 days of IV antibiotics, but cephalexin is only appropriate if the causative organism is susceptible (typically MSSA, streptococci, or common gram-negative urinary pathogens) and the source is not endocarditis, deep-seated abscess, or complicated bacteremia.

Key Decision Points

When Oral Switch is Appropriate

Recent high-quality evidence demonstrates that early transition to oral antibiotics (after 3-7 days of IV therapy for uncomplicated bacteremia) is non-inferior to continued IV treatment 1. The 2024 meta-analysis of 6 RCTs showed no difference in treatment failure rates (OR 0.89,95% CI: 0.54-1.48) and significantly reduced hospital stays by 5.19 days 1.

Critical prerequisites for switching:

• Clinical stability (afebrile, hemodynamically stable, improving inflammatory markers)
• Normal renal function (confirmed in your patient)
• Identified pathogen susceptible to cephalexin
• No endocarditis, epidural abscess, or complicated deep-seated infection
• Functional GI tract with ability to absorb oral medications

Cephalexin-Specific Considerations

Cephalexin has a narrow spectrum compared to many IV agents used for sepsis. It covers 2:

• Susceptible organisms: MSSA (including penicillinase-producing strains), Streptococcus pneumoniae (penicillin-susceptible), Streptococcus pyogenes, E. coli, Klebsiella pneumoniae, Proteus mirabilis
• Resistant organisms: MRSA, enterococci, Enterobacter spp., Pseudomonas, Acinetobacter, penicillin-resistant S. pneumoniae

This is the critical limitation: If your patient's sepsis was caused by organisms outside cephalexin's spectrum, you need a different oral agent.

Dosing Recommendations

For severe infections in adults with normal renal function 2:

• Standard dose: 500 mg every 6 hours (2 g/day)
• Severe infections: Up to 1 g every 6 hours (4 g/day maximum)

Given this patient's age (81 years) and recent sepsis, I recommend 500 mg every 6 hours as the appropriate balance between efficacy and safety. The FDA label explicitly states that for more severe infections or less susceptible organisms, larger doses may be needed 2.

Pharmacokinetic Rationale

Cephalexin achieves peak serum levels of approximately 18 mcg/mL at 1 hour after a 500 mg dose, with measurable levels present for 6 hours 2. It is rapidly absorbed from the upper intestine (not stomach) and 70-100% is excreted unchanged in urine within 6-8 hours 3. The normal half-life is approximately 40-58 minutes with preserved renal function 4.

Duration of Therapy

The total antibiotic duration depends on the source:

• Uncomplicated bacteremia: 7-14 days total (including IV days)
• Complicated infections: Longer courses as clinically indicated

Recent evidence supports that 3 days of effective IV therapy followed by oral completion is reasonable for uncomplicated cases 1. For MSSA vertebral osteomyelitis specifically, at least 3 weeks of IV therapy before oral switch showed 87% success with cephalexin 5, though this is a more complex scenario than typical sepsis.

Common Pitfalls to Avoid

1. Switching without culture data: Never switch to cephalexin without confirmed susceptibility. If cultures are pending or negative, consider broader-spectrum oral agents (fluoroquinolones, amoxicillin-clavulanate) depending on suspected source.

2. Weekend delays: Studies show early switches are rarely advised during weekends 6. Don't let administrative barriers delay appropriate oral transition in a stable patient.

3. Ignoring absorption issues: Cephalexin requires functional GI absorption. Avoid in patients with severe diarrhea, malabsorption, or ileus 3.

4. Underdosing in severe infection: The 250 mg every 6 hours dose is insufficient for post-sepsis patients. Use at least 500 mg every 6 hours 2.

5. Assuming all gram-positives are covered: Enterococci and MRSA are NOT covered by cephalexin 2. If these were isolated, choose vancomycin-equivalent oral agents (linezolid) or daptomycin.

Monitoring After Switch

• Clinical response (fever, vital signs, symptom resolution)
• Inflammatory markers (CRP, WBC) trending downward
• No recurrence of sepsis symptoms
• Ensure patient completes full course (common issue with oral therapy)

The evidence strongly supports oral step-down therapy after brief IV treatment for sepsis in stable patients, but cephalexin's narrow spectrum means it's only appropriate for confirmed susceptible organisms 2, 1.